Back to Journals » Drug Design, Development and Therapy » Volume 14

Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A


Received 17 November 2019

Accepted for publication乐动体育西班牙人 22 January 2020

Published乐动体育西班牙人 3 February 2020 Volume 2020:14 Pages 469—481


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments乐动体育西班牙人 3

Editor who approved publication: Dr Georgios D. Panos

Sandra Le Quellec1,2

1Unité d’hémostase Clinique – Hôpital Cardiologique Louis Pradel – Hospices Civils de Lyon, Lyon, France; 2Service d’hématologie biologique, Groupement Hospitalier Est – Hospices Civils de Lyon, Lyon, France

Correspondence: Sandra Le Quellec
Unité d’Hémostase Clinique, Hôpital Cardiologique Louis Pradel, 59, boulevard Pinel, Bron 69677, France
Tel +33 4 72 11 88 10
Fax +33 4 72 11 88 17

Abstract: Emicizumab is a bispecific, humanized, monoclonal antibody mimicking the factor (F) VIII cofactor activity in mediating the generation of FXa by FIXa in patients with hemophilia A (HA). This subcutaneous non-factor agent has been recently extensively approved for the prophylaxis of patients of HA patients with and without FVIII-inhibitors of all ages, although few data are currently available in children. In Phase 3 clinical trials and case series, emicizumab prophylaxis significantly reduced bleeding rates compared to previous treatment in HA adolescents and children with or without FVIII-inhibitors and was generally well tolerated. In addition, subcutaneous administration of emicizumab provided beneficial effects on health-related quality of life, and lessened the burden of the disease in HA patients as well as in their caregivers. However, additional prospective studies are required to evaluate the long-term safety of emicizumab prophylaxis in very young patients, including previously untreated patients. The aim of this paper was to review the limited data available on the use of emicizumab prophylaxis in children and to highlight the need for further studies to address remaining concerns.

Keywords: emicizumab, hemophilia A, inhibitors, factor VIII, prophylaxis, subcutaneous

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]